Nurix Therapeutics (NRIX) Shares Outstanding (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Shares Outstanding data on file, last reported at $103.4 million in Q1 2026.

• Quarterly Shares Outstanding rose 35.63% year-over-year to $103.4 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $103.4 million (up 35.63% YoY) and the FY2025 annual result came in at $101.8 million, up 34.19% from the prior year.
• Shares Outstanding improved to $103.4 million in Q1 2026 per NRIX's latest filing, from $101.8 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $103.4 million in Q1 2026 and bottomed at $44.9 million in Q1 2022.
• The 5-year median for Shares Outstanding is $49.1 million (2024), against an average of $62.8 million.
• The widest annual swing landed in 2022, when Shares Outstanding grew 1.43%; it then jumped 55.73% in 2024.
• Tracing NRIX's Shares Outstanding over 5 years: stood at $47.2 million in 2022, then rose by 3.28% to $48.7 million in 2023, then surged by 55.73% to $75.9 million in 2024, then surged by 34.19% to $101.8 million in 2025, then climbed by 1.56% to $103.4 million in 2026.
• Per Business Quant, the three latest NRIX Shares Outstanding figures stand at $103.4 million (Q1 2026), $101.8 million (Q4 2025), and $76.9 million (Q3 2025).

Peer Comparison